Archive for the ‘china retractions’ Category
According to the retraction notice in the International Journal of Molecular Medicine, the reader showed the journal that the histological data in two of the figures were from another published paper by different researchers. But when the journal contacted the authors on several occasions, they didn’t hear back.
After the Journal of Medical Entomology (JME) published the study — about the identification of genes that enable an insect to detect odors — an outside researcher wrote a letter to the journal highlighting flaws in the paper. The journal then asked the authors to respond, and enlisted two additional peer reviewers to look into the study, the outside comment, and the authors’ response. They concluded the paper should be retracted.
William Reisen — the journal’s editor-in-chief from the University of California, Davis — said the journal believes the errors were unintentional and there was no fraud on the authors’ part. He added: Read the rest of this entry »
On December 31st 2014, a pioneer in the study of inflammatory bowel disease passed away. An obituary published in the Journal of Digestive Diseases shortly thereafter is typical enough: It describes his achievements, importance to his patients, and battle with pancreatic cancer.
But “Loss in the Last Day of 2014: a Eulogy for Prof. Bing Xia” has now been retracted.
This is the first time we’ve seen an obituary pulled from a journal. Unfortunately, this was not a case of a premature obituary (which happens more often than you’d think)– the researcher did actually die, but it appears the journal published the obituary in the wrong place.
The retraction notice, published earlier this year, explains:
The EOC mentions the lack of reproducibility of the gene-editing technique, known as NgAgo. Alongside it, the journal has published a correspondence which includes data from three separate research groups that cast doubt on the original findings.
According to a spokesperson for the journal, some of the paper’s authors have objected to the decision to issue an EOC.
Earlier this month, we reported on a letter signed by 20 researchers which also raised concerns about the genome-editing activities of NgAgo — and alleged the lab that produced the initial results turned away investigators when they attempted to validate the tool in mammalian cells.
A new letter signed by 20 researchers is casting additional doubts on the validity of a potentially invaluable lab tool — and alleges the lab that produced the initial results turned them away when they tried to replicate its findings in mammalian cells.
In a letter published this week in Protein & Cell, the researchers add their voices to the critics of the gene-editing technique, first described earlier this year in Nature Biotechnology.
The researchers outline their attempts to apply the technique — known as NgAgo — to a variety of cell types, which fell short:
The paper was published in March, 2015 — the same month publisher BioMed Central (BMC) pulled 43 papers for fake reviews.
According to the retraction notice in the European Journal of Medical Research, the authors’ institution in China informed the publisher that the authors had used a third party to help with copyediting and submission to the journal, raising concerns about the authorship of the paper.
According to the retraction notice in the International Journal of Neuroscience, “conflicting messages” were conveyed between the study’s alleged two lead authors, causing the journal to doubt the provenance of the paper.
All the study’s authors are listed as affiliated with The People’s Hospital of Laiwu City in Shandong, China.
No country is immune to misconduct — but some are being more proactive than others.
China, for one, has issued a policy dubbed the “5 don’ts of academic publishing,” which appear to specifically target the ways in which researchers have subverted the peer-review process or hired outsiders to help them with their manuscripts.
An announcement signed by the The Chinese Association for Science and Technology (CAST), Ministry of Education, Ministry of Science and Technology, Health and Family Planning Commission, Chinese Academy of Sciences, Academy of Engineering, and the Natural Science Foundation stipulates: Read the rest of this entry »
According to the EOC, published in RSC Advances, the paper is now under investigation.
Researchers have retracted a systematic review that suggested that antipsychotic drugs are effective and safe for patients with symptoms of dementia — but claim their re-analysis of the updated data still comes to the same conclusions.
According to the retraction notice in Alzheimer’s Research and Therapy, some participants were incorrectly included twice in the meta-analysis.
The corresponding authors recently lost another paper for an entirely different reason — earlier this year, we reported on a retraction in Annals of Neurology for Jin-Tai Yu and Lan Tan, affiliated with the Ocean University of China, Qingdao University, and Nanjing Medical University in China. The authors pulled that paper after appearing to pass off others’ data as their own.